A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; BMI ≥35 required; conditions: Obesity; Cardiovascular Diseases
- Interventions
- Retatrutide; Placebo
- Conditions
- Obesity; Cardiovascular Diseases
- Phase and size
- Phase 3 · 1946 participants
- Dates
- Start 2023-05-30
Primary completion 2026-04-16 - Sponsor
- Eli Lilly and Company (Industry)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Percent Change from Baseline in Body WeightBaseline, Week 80
02Eligibility
Who can take part
Inclusion Criteria: * Have a body mass index (BMI) ≥35.0 kilogram/square meter (kg/m²). * Have established cardiovascular (CV) disease with at least 1 of the following: * prior myocardial infarction * prior ischemic or hemorrhagic stroke, or * symptomatic peripheral arterial disease * Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight. Exclusion Criteria: * Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening. * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. * Have a prior or planned surgical treatment of obesity. * Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening. * Have Type 1 diabetes. * Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had pancreatitis.
03Change log
Registry changes
No changes recorded since the trial was added.